Mineralys Therapeutics, Inc.
MLYS
$27.38
$0.110.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 51.14% | 43.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.44% | -6.93% | |||
| Operating Income | -18.44% | 6.93% | |||
| Income Before Tax | -22.04% | 12.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -22.04% | 12.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.04% | 12.72% | |||
| EBIT | -18.44% | 6.93% | |||
| EBITDA | -18.47% | 6.93% | |||
| EPS Basic | -18.67% | 23.51% | |||
| Normalized Basic EPS | -18.67% | 23.52% | |||
| EPS Diluted | -18.67% | 23.51% | |||
| Normalized Diluted EPS | -18.67% | 23.52% | |||
| Average Basic Shares Outstanding | 2.84% | 14.10% | |||
| Average Diluted Shares Outstanding | 2.84% | 14.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||